Literature DB >> 17301738

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

A-K Hamberg1, M-L Dahl, M Barban, M G Scordo, M Wadelius, V Pengo, R Padrini, E N Jonsson.   

Abstract

The aim of this study was to characterize the relationship between warfarin concentrations and international normalized ratio (INR) response and to identify predictors important for dose individualization. S- and R-warfarin concentrations, INR, and CYP2C9 and VKORC1 genotypes from 150 patients were used to develop a population pharmacokinetic/pharmacodynamic model in NONMEM. The anticoagulant response was best described by an inhibitory E(MAX) model, with S-warfarin concentration as the only exposure predictor for response. Delay between exposure and response was accounted for by a transit compartment model with two parallel transit compartment chains. CYP2C9 genotype and age were identified as predictors for S-warfarin clearance, and VKORC1 genotype as a predictor for warfarin sensitivity. Predicted INR curves indicate important steady-state differences between patients with different sets of covariates; differences that cannot be foreseen from early INR assessments alone. It is important to account for CYP2C9 and VKORC1 genotypes and age to improve a priori and a posteriori individualization of warfarin therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301738     DOI: 10.1038/sj.clpt.6100084

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  59 in total

1.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.

Authors:  Kerenaftali Klein; Ivelina Gueorguieva; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

3.  A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.

Authors:  Qing Xi Ooi; Daniel F B Wright; R Campbell Tait; Geoffrey K Isbister; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

4.  Incremental parameter evaluation from incomplete data with application to the population pharmacology of anticoagulants.

Authors:  Marcel O Vlad; Alexandru Dan Corlan; Federico Morán; Peter Oefner; John Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-19       Impact factor: 11.205

5.  Kinetic laws, phase-phase expansions, renormalization group, and INR calibration.

Authors:  Marcel O Vlad; Alexandru D Corlan; Federico Morán; Rainer Spang; Peter Oefner; John Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-06       Impact factor: 11.205

6.  Development of a novel individualized warfarin dose algorithm based on a population pharmacokinetic model with improved prediction accuracy for Chinese patients after heart valve replacement.

Authors:  Yu-Bin Zhu; Xian-Hua Hong; Meng Wei; Jing Hu; Xin Chen; Shu-Kui Wang; Jun-Rong Zhu; Feng Yu; Jian-Guo Sun
Journal:  Acta Pharmacol Sin       Date:  2017-02-20       Impact factor: 6.150

7.  R-warfarin anticoagulant effect.

Authors:  Roberto Padrini; Luigi Quintieri
Journal:  Br J Clin Pharmacol       Date:  2017-05-11       Impact factor: 4.335

8.  Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.

Authors:  Carlo Federico Zambon; Vittorio Pengo; Stefania Moz; Dania Bozzato; Paola Fogar; Andrea Padoan; Mario Plebani; Francesca Groppa; Giovanni De Rosa; Roberto Padrini
Journal:  Eur J Clin Pharmacol       Date:  2018-02-02       Impact factor: 2.953

9.  Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.

Authors:  Bruce Green; Herta Crauwels; Thomas N Kakuda; Simon Vanveggel; Anne Brochot
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

10.  CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.

Authors:  M V Lima; G S Ribeiro; E T Mesquita; P R Victer; R Vianna-Jorge
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.